Loading
A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by RenovoRx, now recruiting.
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC is a phase 3 interventional study registered as NCT03257033 by RenovoRx, with 190 participants planned, started 2018-03-12 and due to reach its primary completion in 2027-06. Interventions recorded: Gemcitabine, nab-paclitaxel and RenovoCath.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/